Nordisk – Page 8

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis

Ozempic Reduces Mortality Risk by 20% in Diabetes Patients with Chronic Kidney Disease

11 months ago11 months ago talkbio0Tagged Cardiovascular system, Cessation of life, Chronic Kidney Diseases, Diabetes, Failure (biologic function), Kidney, Mortality Vital Statistics, Nordisk, Obesity, semaglutide, Wegovy

** Ozempic, Novo Nordisk, diabetes, chronic kidney disease, mortality risk, cardiovascular deaths, kidney failure, semaglutide, Wegovy, obesity treatment

Lilly’s Weekly Insulin Therapy Excels in Two Major Clinical Trials, Narrowing Gap with Novo Nordisk

11 months ago talkbio0Tagged Administration occupational activities, Clinical Trials, Diabetes, Drug Industry, Eli Lilly, Insulin, insulin therapy, Nordisk, Primary Endpoint, trials, Weekly

Lilly, Novo Nordisk, weekly insulin, primary endpoint, pivotal trials, diabetes management, insulin therapy, clinical trials, diabetes treatment, pharmaceutical industry.

Novo Nordisk’s Wegovy Shines as a Promising Obesity Treatment: A 4-Year Analysis

12 months ago talkbio0Tagged 4-year, Approved, blockbuster drug, Clinical Trials, Glucagon-Like Peptide-1 Receptor, Nordisk, Obesity, semaglutide, United States Food and Drug Administration, Wegovy

Novo Nordisk, Wegovy, obesity treatment, weight loss, 4-year data, clinical trials, blockbuster drug, GLP-1 receptor agonist, FDA approval, semaglutide.

Novo Nordisk’s Wegovy Demonstrates Long-Term Weight Loss Success in New Analysis

12 months ago talkbio0Tagged Analysis of substances, Cardiovascular Diseases, Diabetes, Long-term, Nordisk, Obesity, semaglutide, Wegovy, Weight Loss

Novo Nordisk, Wegovy, weight loss, long-term, four years, analysis, obesity treatment, semaglutide, sustained weight loss, diabetes, cardiovascular disease.

Novo Nordisk and Metaphore Pharmaceuticals Join Forces in a $600 Million Partnership to Pioneer Innovative Obesity Treatments

12 months ago talkbio0Tagged Metabolic Diseases, next-generation, Nordisk, Obesity, Partnership, pharmaceutical collaboration, weight loss medications

Novo Nordisk, Metaphore Pharmaceuticals, obesity drugs, next-generation treatments, $600 million deal, partnership, pharmaceutical collaboration, weight loss medications, metabolic disorders.

Federal Trade Commission Challenges Novo Nordisk’s Ozempic and Over 300 ‘Junk’ Patent Listings in FDA Database

12 months ago talkbio0Tagged Drug Development, Drug Industry, heroin, Intellectual Property, Legal patent, Nordisk, Ozempic, United States Federal Trade Commission, United States Food and Drug Administration

FTC, Novo Nordisk, Ozempic, FDA, patent listings, crackdown, junk patents, pharmaceutical industry, intellectual property, drug development.